This morning Roche announced that it is buying GeneWEAVE BioScience, an American diagnostics firm, for almost $425 million. Roche is planning to expand its promise to find the right drugs to fight against “superbugs” or viruses that are drug-resistant.
In this morning’s announcement Roche stated that it would initially pay shareholders of the American company $190 million and a further $235 million contingent to the future success of its medications.
Roche is pleased to have the access it always wanted from GeneWEAVE, the American company has focused on fighting the war against “superbugs” for over half a decade have even created the “Smarticles” technology. The technology allows those who are examining, identify the organisms at a much faster rate.
Roche has been trying it make a name in the antibacterial sector since 2013 when they acquired Polyphor a developer of new medicine for resistant bacteria. Some believes that Roche is a company that constantly falls short of expectations, but if the company can develop the proper drug to treat the growing threat of “superbugs” then it will surely have a level up against the competition.